Corlieve Therapeutics

Corlieve Therapeutics was founded in November 2019 with the mission of bringing new treatment options to patients with severe neurological disorders. The company’s founders, Richard Porter, Valerie Crepel, and Christophe Mulle, combined their expertise in neuroscience research, epileptology, and global drug discovery and development for neurological diseases. Backed by international life science investors Kurma Partners and Idinvest Partners, as well as leading AAV gene therapy company REGENXBIO, Corlieve Therapeutics was established. Corlieve is currently advancing its lead program in collaboration with Inserm, CNRS, and REGENXBIO, and has licensed REGENXBIO’s NAV AAV9 technology.